000			03561nam a22003615i 4500
999			_c80119 _d80119 _x1
001			80119
003			ES-MaUEC
005			20230207040254.0
007			cr nn 008mamaa
008			141008s2014 xxk| s |||| 0|eng d
020			_a9781447165033
024	7		_a10.1007/978-1-4471-6503-3 _2doi
040			_dES-MaUEC
050		4	_aRC382 _b.L486 2014
245	1	0	_aLevodopa-Induced Dyskinesia in Parkinson's Disease _cedited by Susan H. Fox, Jonathan M. Brotchie.
260			_aLondon _bSpringer International Publishing _c2014
300			_a1 recurso en línea (XII, 368 p.) _b12 ilustraciones, 11 ilustraciones en color
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_aPhenomenology of Levodopa-Induced Dyskinesia -- Dyskinesia Rating Scales in Parkinson's Disease -- Epidemiology of Levodopa-Induced Dyskinesia -- Risk Factors for Levodopa-Induced Dyskinesia -- Pharmacological Treatment Options for Levodopa-Induced Dyskinesia -- Surgical Options for Levodopa-Induced Dyskinesia in Parkinsonâ€{u3804}isease -- Basal Ganglia Circuitry Models of L-DOPA-Induced Dyskinesia -- Basal Ganglia Circuitry Models of L-DOPA-Induced Dyskinesia -- Pharmacological Properties of Levodopa -- Dopamine Receptors and LID -- The Serotonergic System In Levodopa-Induced Dyskinesia -- The Opioid System in Levodopa-Induced Dyskinesia -- Glutamate Receptors and Levodopa-Induced Dyskinesia -- Cannabinoids and Levodopa-Induced Dyskinesia -- The Role of the Noradrenergic System and its Receptors In Levodopa-Induced Dyskinesia -- Involvement of the Cholinergic System in Levodopa-Induced Dyskinesia -- New Clinical Trials for Levodopa-Induced Dyskinesia -- Preclinical Models of Levodopa-Induced Dyskinesia -- Final Thoughts: Summary and Future Therapeutic Strategies in LID.
520			_aThis book aims to provide a single reference source on levodopa-induced dyskinesias (LID) from â€b̃ench to bedsideâ€{uE809}nitial chapters review the clinical features and phenomenology of LID with video examples; epidemiology and genetic risk factors for LID are covered as a background to understanding risk factors for developing LID. The following chapters cover the latest preclinical studies aiming to understand the pathophysiology of LID at the cellular, neurochemical, neurophysiological and circuitry level with detailed discussion of mechanisms and future directions to take the field forward; clinical studies from phase II to phase IV; ongoing RCTs in LID; and evidence-based medicine reviews of treatment options.Âv̥odopa-Induced Dyskinesia in Parkinsonâ€{u3804}isease is aimed at an international audience of movement disorder neurologists; neuroscientists; trainees; and graduate and post-graduate students.
650		7	_2embne _aSistema nervioso central _xEnfermedades _9188115
650		7	_2embne _9141804 _aParkinson, Enfermedad de
700	1		_aFox, Susan H. _eeditor literario _0Local _988026
700	1		_aBrotchie, Jonathan M. _eeditor literario _0Local _988027
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-1-4471-6503-3 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
907			_a.b12878728 _b10-10-17 _c11-11-15
942			_2lcc _cLE
945			_aRC382 .L486 2014 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11558544 _z06-04-17
988			_aEBSPRINGER
998			_am _a_alco _a_vill _b11-11-15 _cm _dz _e- _feng _gxxk _h0